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Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and accounts for the
third-leading cause of cancer-related deaths. Over the past decades, advances have been made in the field of
surgery, but effective treatment of HCC is lacking. Due to a marked male predominance in morbidity and mortality
in HCC patients, it has long been considered that sex hormones play a role in HCC development. Recently estrogen
has been proven to exert protective effects against HCC through IL-6 restrictions, STAT3 inactivation and
tumour-associated macrophage inhibition. While IL-6-dependent STAT3 activation is considered a key event in
inflammation-induced liver cancer, the anti-inflammation effect of estrogen is well documented. The roles of the
estrogen receptor and aromatase and interactions between microRNAs and estrogen in HCC have been
investigated. In this review, we present a novel model to elucidate the mechanism of estrogen-mediated inhibition
of HCC development through an anti-inflammation effect and provide new insights into the roles of estrogen in
liver disease.
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The treatment of liver cancer is a difficult task, espe-
cially among end-stage patients, whose lesions are usu-
ally thought to be unresectable. The development of
HCC is considered the end result of most liver diseases,
including viral hepatitis, cirrhosis and alcoholic liver dis-
ease. As a result of high-grade malignancy and lack of
effectiveness of medical treatment, HCC is the third-
leading cause of cancer deaths worldwide [1]. Further-
more, the incidence of HCC shows a regional divergence
due to aetiology. In high-risk areas such as Southeast
Asia and China, hepatitis B virus (HBV) infection, to-
gether with aflatoxin exposure, is the predominant risk
factor. However, hepatitis C virus (HCV) infection has
emerged as a more significant risk factor in Japan, North
America and Europe. In these developed countries, the
incidence of HCC is increasing [2,3].
Until now, only sorafenib is used as first-line therapy for
patients with advanced HCC [4,5]. Sorafenib therapy for
HCC has been proven to be safe and effective. Despite a
statistically significant and clinically relevant improvement* Correspondence: cxjzu@zju.edu.cn
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unless otherwise stated.in median overall survival (OS) with sorafenib, some im-
portant questions of its application in advanced HCC re-
main unanswered [6]. For the better use of sorafenib in
the clinical setting, the dosage, outcome prediction based
on side effects and application of modified Response
Evaluation Criteria in Solid Tumours (mRECIST) require
more evaluation. Interested in obvious gender disparity in
HCC occurrence [7,8], researchers have attempted to
investigate the molecular mechanism underlying such dis-
parity and developed effective therapy using sex hor-
mones. Recently, work by Ma et al. showed an exciting
potential of the combination of sorafenib and hormone-
related therapy in HCC, which will be a better way to con-
trol advanced HCC [9].
Unlike breast and prostate cancer, which are modu-
lated by estrogen and androgen, respectively, HCC may
be modulated by both sex hormones during its initiation,
progression and metastasis [8,10,11]. Elevated levels of
androgen are considered to promote tumourigenesis,
while studies in the past decades showed that the roles
of estrogen in HCC are diverse, even opposite [8,12-14].
Fortunately, recent progress has shed some light on the
precise mechanism of estrogen action in HCC. Although
many aspects are still unknown, the anti-HCC activity of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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fect might be related to its anti-inflammation effect. We
thus assume that this anti-inflammation effect may pro-
vide a key to understanding the role of estrogen in HCC.
More importantly, the anti-inflammation nature of es-
trogen may yield a new, promising approach to treat
HCC. In this review, we focus on recent studies regard-
ing the potential roles of estrogen in HCC.Early clinical trials of anti-estrogen therapy for HCC
At the very beginning of anti-estrogen therapy in med-
ical practice, clinicians were inspired by the success of
tamoxifen, which is a competitive antagonist of the
estrogen receptor (ER), as a treatment for ER-positive
breast cancer. In addition, estrogen was found to pro-
mote HCC in rats [15-19]. Some reports also showed
that oral contraceptives (OCPs) led to a higher incidence
of liver diseases such as focal nodular hyperplasia, liver
haemangioma and hepatocellular adenoma, which are
considered premalignant stages of HCC [20,21]. How-
ever, a systematic review concluded that no benefits
could be gained by anti-estrogen in regards to overall
survival and life quality [22]. And it is also suggested
that OCPs might not to be a risk factor for HCC [23].
As a result, several hypotheses were proposed to explain
the failures of using anti-estrogen in treating HCC, in-
cluding the dysfunction induced by variant ER-α (vER-α)
[24,25], regulation by the postreceptor signalling path-
way and treatment with an insufficient therapy dose
[26,27]. With further investigations, estrogen was found
to suppress HCC [28], and this was supported by epi-
demiology data, which suggested an elevated incidence
of HCC in postmenopausal female and suppression of
such phenomenon by estrogen treatment [29,30]. More-
over, the prognosis of female HCC patients is much bet-
ter than male patients [31]. These findings all imply that
estrogen may act as a protective factor against HCC. Un-
fortunately, estrogen-related treatment is still impractical
so far due to our limited knowledge [22].ER-α may be crucial to the estrogen-induced effect on HCC
The initiation of the canonical estrogen pathway de-
pends on the binding of estrogen and its receptor. The
ligand-bound ER then recognizes the estrogen response
element (ERE) and regulates the transcription of target
genes. Two subtypes of ERs have been found to date,
ER-α and ER-β. Both ER subtypes are expressed in HCC
and interact with each other [32]. Studies have shown
that ER subtypes exert multiple functions in various
stages of liver disease and participate in an extremely
complicated signal transduction process. The different
roles of the ER subtypes in liver disease, especially ER-β,
have yet to be fully elucidated. Nevertheless, ER-α hasbeen identified for a long time and has been extensively
investigated [8].
Wild type ER-α (wtER-α) contains 595 amino acid resi-
dues with a molecular mass of 66 kDa. It consists of a
ligand-independent activation function domain (AF-1), a
central DNA-binding domain (DBD) and a hormone-
binding domain (HBD, also named ligand-dependent acti-
vation function domain, AF-2). The DBD and the HBD
are linked by a hinge region [33]. Different ER-α splice
variants, including ER-αΔ5 (incomplete HBD), ERα-46
(AF-1 deleted) and ERα-36 (AF-1 deleted and incomplete
HBD), have been identified in the liver (Figure 1) [34,35].
The ER-α variants have been proven to be strong negative
predictors for HCC [25,36,37]. ER-αΔ5 and hepatitis B
virus X protein (HBx) can repress the transcriptional ac-
tivity of wtER-α through an 17β-estradiol (E2)-independ-
ent method, and histone deacetylase-1 (HDAC-1) seems
to be involved in the process [38].
A different expression pattern of vER-α can be observed
in normal liver, cirrhosis and HCC tumour tissues (Table 1)
[34], and a similar result can be obtained in liver cell lines.
Furthermore, ER-α seems to lose function during liver dis-
ease progression, and dysfunctional ER-α could contribute
to HCC development. In addition, ERα-36 negatively
regulates the transcriptional activity of ER-66 and ER-β
[39]. This crosstalk between ER subtypes forms a part of
the complex ER signalling and has yet to be confirmed
in HCC.
However, vER-α is considered a predictor of poor
prognosis both in HCC and breast cancer [33]. In
multiple-factor analysis, the ER-α type and bilirubin level
were two independent risk factors for HCC [36]. The
worst prognosis appears in patients with vER-α and
hepatitis B surface antigen (HBS-Ag), and this may be
explained by the suppression of transcriptional activity
of the ER-α by HBx and ER-αΔ5. In addition, HBV in-
fection could lead to genomic instability, which may
contribute to the expression of vER-α [40]. Although
tumour size was not obviously different in groups with
different ERα types, vER-α-positive HCC presents a
rapid growth rate and an increased ability of metastasis
[36]. Therefore, vER-α-positive patients usually die of
massive tumour invasion. In contrast, slow progressive
liver failure due to cirrhosis kills wtER-α-positive HCC
patients. Based on this finding, Villa et al. proposed that
the treatment for wtER-α HCC patients should focus on
chronic liver failure [36,41]. Furthermore, vER-α in
chronic hepatitis and cirrhosis is also associated with
high levels of oxidative stress-induced DNA damage and
c-myc expression [42].
Recently, hypomethylation of the long interspersed nu-
clear element-1 (LINE-1) promoter was reported to cor-
relate with poor outcomes of HCC [43]. Before this
finding, LINE-1 hypomethylation was more frequently
Figure 1 Four types of ER-α variants in the liver. Alternative splicing events generate several different isoforms of ER-α. In the liver, all types of
ER-α have been reported and play a role in HCC. These variants are mainly AF-1- or HBD-depleted. ERα-36 has an additional 27-amino-acid
sequence at its COOH terminus.
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methylation of the ER promoter [44,45]. This hyperme-
thylation of CpG islands in wtER genes may partially
contribute to the significant downregulation of wtER
and upregulation of vER-α in HCC [46]. The mechanism
by which the expression pattern of the ER-α subtype is
changed during liver tumourigenesis remains largely un-
known. With more conclusive evidence, the expression
pattern of the ER-α subtypes could serve as a potential
prognostic indicator for HCC and provide a novel target
for HCC treatment.
Anti-inflammation effects of estrogen
The multitasking role of estrogen in inflammation is
dependent on its concentration, cell type and context, and
the anti-inflammation effect of estrogen has been further
confirmed in many disease models, including liver disease.
If B cell-dependent immunity or an overshooting fibrotic
tissue repair process does not play a central role, estrogen
would have a protective effect in chronic inflammatory
diseases [47]. Some cytokines contribute to the occurrence
of liver disease, and possible effects of estrogen on the re-
lease of proinflammatory cytokines in vitro have been dis-
cussed in a previous review (Table 2) [47].
Moreover, estrogen could inhibit the NF-κB pathway
and block the expression of adhesion molecules. Inflam-
mation factors, such as nitric oxide (NO) and reactive
oxygen species (ROS) production are also downregulated
in inflammation milieus. Given the emerging concept of
cancer-related inflammation, it is of scientific and clin-
ical interest to explore the possibility of using the anti-
inflammation effect of estrogen in HCC prevention.Table 1 The expression pattern of ER-α subtypes in different
liver tissues
Normal liver Cirrhosis HCC
ERα-66 High Moderate None
ERα-46 Moderate Moderate Moderate
ERα-36 None Moderate HighIL-6 inhibition by estrogen
Hepatoma has been considered an inflammation-related
cancer caused by chronic hepatitis [59-61]. During chronic
inflammation, proinflammatory cytokines and immune
cells create a tumour microenvironment that influences
hepatocarcinogenesis. Among these, IL-6 is believed to be
a key component in inflammation-associated tumourigen-
esis [62-64]. More importantly, estrogen has a significant
impact on the production of IL-6. Preliminary studies
showed that elevated IL-6 expression was associated with
a high rate of metastasis and poor prognosis in HCC
[63-65]. Concordant evidence from Naugler’s group
showed that MyD88-dependent production of IL-6 con-
tributed to gender disparity of HCC because IL-6 ablation
protected male mice from HCC and that estrogen inhib-
ited IL-6 production [51].
In the liver, the release of IL-6 from Kupffer cells
(KCs) is modulated by MyD88-dependent NF-κB signal-
ing, whose activation is triggered by IL-1α from dying
hepatocytes [66-68]. According to the report by Naugler
et al., E2 treatment could reduce diethylnitrosamine
(DEN)-induced liver injury by inhibiting IL-6 production
from KCs [51]. Moreover, E2 also provides protection in
IL-6-treated mice, which suggests that E2 may inhibit
downstream IL-6 signalling. The inhibition of the IL-6
promoter activity through inactivation of NF-κB and C/
EBPβ causes downregulation of IL-6 [69]. These studies
provide promising evidence for the higher incidence of
HCC in males than females based on the role of IL-6 in
anti-inflammatory effects [70]. However, a recent study
on Forkhead box A (Foxa)-deficient mice showed that
the IL-6 level did not correlate with tumour load when
Foxa1/2 were only ablated in hepatocytes [71]. However,
inflammatory monocytes that were recruited from circu-
lation after HCC initiation exerted multiple effects on
the tumour microenvironment. During HCC progres-
sion, tumour-associated macrophages (TAMs) replace
KCs as the dominant modulator [61]. Taken together,
these findings suggest that IL-6 is one of the regulators
involved in the sexual dimorphism of HCC.
Table 2 Summary of possible effects of estrogen on
cytokine production in vitro
Cytokines Effects of estrogen on cytokine production References
IL-1 Heterogeneous, depends on E2 concentration [48,49]




TNF Mostly inhibition [48,54]
IFN-γ Heterogeneous, depends on cell type [54,55]
IL-4 Promotion [55]
IL-10 Mostly promotion [54,56]
TGF-β Promotion [57,58]
RA: rheumatoid arthritis.
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Signal transducer and activator of transcription-3 (STAT3)
has been identified as a key regulator of macrophage func-
tions and is involved in several programmes related to
tumour progression [72-75]. Moreover, STAT3 signalling
is a central signalling hub in cancer-related inflammation.
The inflammatory microenvironment is orchestrated by
numerous cytokines, chemokines and other mediators,
and STAT3 is critical in regulating these inflammatory
factors, such as IL-6, macrophage colony-stimulating fac-
tor, prostaglandin and cyclooxygenase-2 [76]. In STAT3-
deficient mice, the liver tumour load caused by DEN treat-
ment was significantly reduced [77]. In addition, the JAK/
STAT3 pathway was enhanced in suppressor of cytokine
signalling-3 (SOCS3) knockout mice, which were sensitive
to hepatitis-induced hepatocarcinogenesis [78]. STAT3
signalling is negatively regulated through feedback loops.
However, the polarization of macrophages to the M2
phenotype disturbs this homeostasis and keeps STAT3
activated; this, in turn, attenuates anti-tumour immune re-
sponses [79].
Recently, Hou et al. found that ER-α could suppress
STAT3 activity in HCC cell lines and tumour tissues by
elevating the expression of protein tyrosine phosphatase
receptor type O (PTPRO) in female mice [80]. In E2-
treated mice, an increased PTPRO level significantly
inhibited HCC. Mechanistically, ER-α binds to EREs on
the promoter of PTPRO then increases its expression.
Moreover, it was found that the promoter region is
methylated, which inactivates the PTPRO gene in HCC
in human and rat models [81,82]. Methylation-mediated
silencing of suppressor genes promotes carcinogenesis
[83,84], but the methylation of ptpro that is modulated
by ER-α must still be confirmed. In addition, this group
found that PTPRO dephosphorylated STAT3 at Y705
and S727 then attenuated STAT3 signalling. Therefore,
we could conclude that ER-α regulates STAT3 signalling
by inhibiting IL-6 before STAT3 activation and directly
suppressing STAT3 activity through PTPRO activation.Recruitment of ER-α depends on FOXA1/2
To exert multiple functions of estrogen, a ligand-bound
ER must recognize ERE in target promoters. Previous
studies have shown Foxa1/2 are involved in liver develop-
ment and biological activity [85-88]. Additionally, in breast
and prostate, the recruitment of ER-α and androgen re-
ceptor (AR) to target genes depends on FOXA1 [89-91].
No protective effect of estrogen could be observed in
FOXA-deficient mice, and ER-α and AR exerted protect-
ive and oncogenic functions in HCC in a FOXA1/2-
dependent manner [71]. According to this work, ER-α and
AR are recruited to their target genes with assistance from
FOXA1/2, and an ERE/ARE is found to be adjacent to
FOXA binding sites on promoters. Moreover, an abun-
dance of single nucleotide polymorphisms (SNPs) of
the FOXA2 binding site is found on target genes during
HCC progression in women due to attenuated affinity of
FOXA2 and ER-α for their targets. In their study, estrogen
was also found to enhance liver injury in mutant mice. In
addition, genotoxic metabolites from estrogen contribute
to carcinogenesis [92], hence, raising the notion that estro-
gen action in the liver is determined by the overall cellular
context, rather than the hormone itself.
Some microRNAs promote HCC through inhibiting ER-α
Previous studies found that miR-22 was downregulated
in HCC and considered as a suppressor of cell prolifera-
tion [93]. However, Jiang et al. found that miR-22 was
highly expressed in male HCC tumour adjacent tissue,
and this expression was correlated with decreased ERα
expression [66]. Furthermore, they showed that miR-22
inhibited ER-α transcription by directly targeting its 3′-
UTR region, which was consistent with a previous study
[94]. The deprivation of the anti-tumour effect of ER-α
caused by miR-22 led to the carcinogenic process of ad-
jacent liver tissues. Intriguingly, miR-18a, which has a
high expression pattern in HCC tumour tissues, was also
found to suppress the transcription of the ER-α gene
[95]. However, miR-18a was not an inducer of female be-
nign hepatoma in their research, which supported the
notion that HCC and benign hepatoma are caused by
distinct mechanisms. Actually, malignant transformation
of OCPs-induced hepatic adenoma made estrogen as a
HCC-promoting factor in early clinical trials [10].
Another study raised the possibility that miR-26a
could prevent hepatoma cell growth through the repres-
sion of ER-α [96]. However, the marked decrease of ER-
α and miR-26a in HCC tumour tissues indicated that
downregulation of ER-α in HCC is mediated by a com-
plex cellular network and not only by miR-26a.
Role of ER-β in liver disease requires more investigation
ER-β shows strong anti-proliferative [97,98] and anti-
inflammatory properties [99], and it is detected more
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those with HCC [32], which implicates a protective role
of ER-β in liver disease. Moreover, it has been shown
that ER-β is overexpressed in HCV-related HCC tissues,
but not in HBV-related tissues [100], suggesting that dif-
ferent mechanisms of HCC progression are induced by
HCV and HBV. However, previous work showed the
HBsAg could upregulate ER-β in HBsAg transgenic male
mice, which raises the possibility that HBV infection
may contribute to the gender disparity of HCC [101]. In-
triguingly, ER-β displays anti-tumour effects in intrahe-
patic cholangiocarcinoma (IHCC) [102]. We believe that
a better understanding of the roles of ER-β in liver dis-
ease will yield opportunities to develop novel therapies.
TAMs define an invasive microenvironment to pro-
mote tumour progression through multiple signalling
pathways [103,104]. M2-polarised TAMs promote angio-
genesis, metastasis and immune suppression by the se-
cretion and modulation of cytokines, chemokines and
growth factors [61]. A recent report revealed that the in-
hibition of the JAK/STAT6 pathway reduced TAMs
polarization, thus suppressing HCC growth [105]. Such
an effect is specifically caused by ER-β-induced SOCS1
expression. This finding indicates the protective role of
estrogen through ER-β binding, but intriguingly, ER-β
restrains the progression and metastasis of hepatoma
[105]. In addition, unliganded ER-β regulates three clas-
ses of genes, whereas ER-α must be ligand-bound to
regulate its target genes [106]. These findings provide
novel insights into the role of ER-β in liver cancer.Figure 2 Estrogen inhibits HCC development through its anti-inflamm
pathways in KCs and hepatocytes. Ligand-bound ER-β inhibits M2 phenoty
in TAMs, and not in KCs. Several miRNAs promote HCC by inhibiting ER-α.
and STAT3 plays a central role in these axes. Necrosis caused by liver injury
leads to HCC.Unfortunately, the function of ER-β in HCC is largely
unclear and requires further investigation.The synthesis of estrogen by aromatase in HCC
Elevated aromatase expression has been detected in
hepatitis and HCC [107-109]. Intratumoural aromatase
is considered a key inducer of estrogen-dependent
neoplasm, such as breast, endometrial, and surface
epithelial-stromal ovarian carcinomas [110]. The aro-
matase inhibitor fadrozole hydrochloride was demon-
strated to counter spontaneous HCC in rats [111].
However, the contribution made by aromatase to the
tumour microenvironment has not yet clarified. The el-
evated activity and expression of aromatase was de-
tected in malignant human liver tissues and cells [108],
and the influence of polymorphisms of the CYP19 (aro-
matase) promoter is associated with risk for HCC [112].
However, no conclusive evidence could be found to
mechanistically link local estrogen production to HCC
development. Consistent with the notion that estrogen
prevents HCC by anti-inflammation effect, aromatase
was found to be a risk factor only in non-viral hepatitis-
related HCC.Conclusion
The effect of estrogen in HCC has turned from an onco-
genic to protective role based on recent discoveries. An-
drogen promotes the development of liver and prostate
cancer [113,114], whereas estrogen plays an oppositingatory effects. Estrogen exerts its protective effects through different
pe polarization in the ANA-1 cell line, and this procedure occurs mainly
FOXA1/2 assists a ligand-bound ER-α to locate and bind to the ERE,
defines the inflammatory microenvironment in the liver and eventually





IL-6 DEN-treated mice [51]
STAT3 DEN-treated mice, Huh-7 cells, SMCC-
7721 cells
[51,80]
NF-κB DEN-treated mice, HepG2 cells, H22 cells [51,118,121]
TAMs Orthotopically and ectopically implanted
HCC mice, coculture system of
macrophages and Hepa1-6 cells
[105]
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[51,115,116]. How does such an antagonism exist? Pion-
eer work on this issue revealed that synthetic estrogen
might promote liver carcinogenesis after DEN treatment
in animal models [15-19]. Indeed, the precedence of es-
trogen or DEN treatment seems to have opposite effects
on HCC development. Administration of estrogen prior
to carcinogenic events such as DEN treatment, is be-
lieved to protect the liver from HCC [28], and this
phenomenon is supported by a human model because
estrogen usually functions in females before HCC initi-
ation. Another possible mechanism for the oncogenic ef-
fect of estrogen is illustrated in the DEN-treatment
model, where the NF-κB pathway is inhibited in hepato-
cytes (not in KCs). Blockage of NF-κB signalling in
DEN-treated hepatocytes promotes carcinogenesis, be-
cause hepatocytes suffer severe cell death through ne-
crosis and apoptosis [67]. In contrast, the inhibition of
NF-κB signalling has a suppressive effect in hepatocytes
of Mdr2−/− mice, which is an inflammation-associated
liver cancer model [68], consistent with the result in
Huh7 cells [117]. Moreover, estrogen is found to attenu-
ate HCC progression by regulating cell proliferation, in-
vasion and apoptosis by inhibiting ER-α-induced NF-κB
signalling [118]. NF-κB is highly associated with cancer-
related inflammation, and estrogen inhibits NF-κB sig-
nalling; therefore, a novel model that fully captures the
complex behavior of human HCC generation is required
to understand the molecular mechanism by which the
origin of HCC is modulated [119].
With emerging evidence supporting HCC as an
inflammation-related cancer [59], we speculate that es-
trogen may, at least partially, play its protective role
through its anti-inflammation effects. As described in
detail in Figure 2, estrogen is involved in the regulation
of the inflammation network in HCC by restraining of
proinflammatory cytokines and inhibiting downstream
signalling pathways. However, it is also reported that es-
trogen promotes hepatocytes proliferation [120]. Here,
we believe that estrogen exerts promoting and inhibiting
effects on HCC development, but, in tumour milieus, it
is generally accepted as a mediator of anti-inflammation.The oncogenic effect of estrogen could also play a part
in tumourigenesis, as cancer cells will use all of the help
they can get. That is, both faces of estrogen are retained
in HCC, but it protects females from HCC because in-
flammation is the key event for HCC development. The
cellular milieus help estrogen protect from liver cancer.
However, evidence for the anti-inflammatory effect of
estrogen in HCC is limited; and uncovering how estro-
gen protects from HCC development would provide
novel therapeutic approaches in drug design and cancer
therapy (Table 3).
It is important to bear in mind; however, that estrogen
may cause some adverse effects in patients, especially in
males, who form the majority of HCC cases. Therefore,
the method for using hormone-related therapy to treat
HCC requires rigorous testing and validation. In the fu-
ture, finding the exact point at which estrogen switches
its role from oncogenic to suppressive in HCC will en-
able us to establish a model to mimic chronic inflamma-
tion during HCC development.
Abbreviations
HCC: Hepatocellular carcinoma; ER: Estrogen receptor; OCPs: Oral
contraceptives; ERE: Estrogen response element; wtER-α: Wild type ER-α;
vER-α: Variant ER-α; E2: Estradiol; HBx: Hepatitis B virus X protein;
HBS-Ag: Hepatitis B surface antigen; LINE-1: Long interspersed nuclear
element-1; KCs: Kupffer cells; DEN: Diethylnitrosamine; Foxa: Forkhead box A;
TAMs: Tumour-associated macrophages; STAT: Signal transducer and
activator of transcription; SOCS: Suppressor of cytokine signalling;
PTPRO: protein tyrosine phosphatase receptor type O.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LS performed article searches, drafted the manuscript and figures and
revised the manuscript. YF performed language correction and contributed
to refinement of the manuscript. HL and RM participated in information
updating and viewpoint complementarity. XC provided the original idea,
administrative support and financial support. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported by National Natural Science Foundation of China
(81201942). We thank Yongjie Yin for his help in figure preparation and
Anyong Xie for reading the manuscript and making corrections.
Received: 18 December 2013 Accepted: 28 March 2014
Published: 8 April 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular
carcinoma: epidemiology, risk factors and pathogenesis. World J
Gastroenterol 2008, 14:4300–4308.
3. Venook AP, Papandreou C, Furuse J, de Guevara LL: The incidence and
epidemiology of hepatocellular carcinoma: a global and regional
perspective. Oncologist 2010, 15(Suppl 4):5–13.
4. Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: a
systematic review. Liver Cancer 2012, 1:144–158.
5. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update.
Hepatology 2011, 53:1020–1022.
6. Abou-Alfa GK: Sorafenib use in hepatocellular carcinoma: more questions
than answers. Hepatology 2014.
Shi et al. Journal of Translational Medicine 2014, 12:93 Page 7 of 9
http://www.translational-medicine.com/content/12/1/937. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide
incidence and trends. Gastroenterology 2004, 127:S5–S16.
8. Kalra M, Mayes J, Assefa S, Kaul AK, Kaul R: Role of sex steroid receptors in
pathobiology of hepatocellular carcinoma. World J Gastroenterol 2008,
14:5945–5961.
9. Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh
S, Chang C: Hepatic androgen receptor suppresses hepatocellular
carcinoma metastasis through modulation of cell migration and anoikis.
Hepatology 2012, 56:176–185.
10. Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto
G: Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006,
1089:228–236.
11. De Maria N, Manno M, Villa E: Sex hormones and liver cancer. Mol Cell
Endocrinol 2002, 193:59–63.
12. Pignata S, Daniele B, Gallo C, De Vivo R, Monfardini S, Perrone F: Endocrine
treatment of hepatocellular carcinoma. Any evidence of benefit?
Eur J Cancer 1998, 34:25–32.
13. Farinati F, De Maria N, Marafin C, Fagiuoli S, Della LG, Naccarato R:
Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a
pathogenetic factor? Eur J Gastroenterol Hepatol 1995, 7:145–150.
14. Shimizu I, Yasuda M, Mizobuchi Y, Ma YR, Liu F, Shiba M, Horie T, Ito S:
Suppressive effect of oestradiol on chemical hepatocarcinogenesis in
rats. Gut 1998, 42:112–119.
15. Campen D, Maronpot R, Lucier G: Dose–response relationships in
promotion of rat hepatocarcinogenesis by 17 alpha-ethinylestradiol.
J Toxicol Environ Health 1990, 29:257–268.
16. Yager JJ, Yager R: Oral contraceptive steroids as promoters of
hepatocarcinogenesis in female Sprague–Dawley rats. Cancer Res 1980,
40:3680–3685.
17. Yager JD, Campbell HA, Longnecker DS, Roebuck BD, Benoit MC:
Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol
and mestranol but not estradiol. Cancer Res 1984, 44:3862–3869.
18. Cameron R, Imaida K, Ito N: Promotive effects of ethinyl estradiol in
hepatocarcinogenesis initiated by diethylnitrosamine in male rats. Gann
1981, 72:339–340.
19. Wanless IR, Medline A: Role of estrogens as promoters of hepatic
neoplasia. Lab Invest 1982, 46:313–320.
20. Fechner RE: Benign hepatic lesions and orally administered
contraceptives. A report of seven cases and a critical analysis of the
literature. Hum Pathol 1977, 8:255–268.
21. Vana J, Murphy GP, Aronoff BL, Baker HW: Primary liver tumors and oral
contraceptives. Results of a survey. JAMA 1977, 238:2154–2158.
22. Di Maio M, De Maio E, Morabito A, D’Aniello R, De Feo G, Gallo C, Perrone F:
Hormonal treatment of human hepatocellular carcinoma. Ann N Y Acad
Sci 2006, 1089:252–261.
23. Maheshwari S, Sarraj A, Kramer J, El-Serag HB: Oral contraception and the
risk of hepatocellular carcinoma. J Hepatol 2007, 47:506–513.
24. Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafoco P, Merighi A,
Ferretti I, Esposito P, Miglioli L, Bagni A, Troisi R, De Hemptinne B, Praet M,
Callea F, Manenti F: Variant liver estrogen receptor transcripts already occur
at an early stage of chronic liver disease. Hepatology 1998, 27:983–988.
25. Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, Pompei G,
De Santis M, Ferrari A, Manenti F: Type of estrogen receptor determines
response to antiestrogen therapy. Cancer Res 1996, 56:3883–3885.
26. Tan CK, Chow PK, Findlay M, Wong C, Machin D: Use of tamoxifen in
hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol
Hepatol 2000, 15:725–729.
27. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC: High-
dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:
a multicenter randomized controlled trial. Hepatology 2002, 36:1221–1226.
28. Villa E: Role of estrogen in liver cancer. Womens Health (Lond Engl) 2008,
4:41–50.
29. Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, Lee SD, Lin CL, Chen
PJ, Lin SC, Chen CJ: Role of reproductive factors in hepatocellular
carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003,
38:1393–1400.
30. Shimizu I: Impact of oestrogens on the progression of liver disease.
Liver Int 2003, 23:63–69.
31. El-Serag HB, Mason AC, Key C: Trends in survival of patients with
hepatocellular carcinoma between 1977 and 1996 in the United States.
Hepatology 2001, 33:62–65.32. Iavarone M, Lampertico P, Seletti C, Francesca DM, Ronchi G, Del NE,
Colombo M: The clinical and pathogenetic significance of estrogen
receptor-beta expression in chronic liver diseases and liver carcinoma.
Cancer 2003, 98:529–534.
33. Barone I, Brusco L, Fuqua SA: Estrogen receptor mutations and changes in
downstream gene expression and signaling. Clin Cancer Res 2010,
16:2702–2708.
34. Miceli V, Cocciadiferro L, Fregapane M, Zarcone M, Montalto G, Polito LM,
Agostara B, Granata OM, Carruba G: Expression of wild-type and variant
estrogen receptor alpha in liver carcinogenesis and tumor progression.
OMICS 2011, 15:313–317.
35. Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, Buttafoco P, Losi
L, Manenti F: Variant estrogen receptor messenger RNA species detected in
human primary hepatocellular carcinoma. Cancer Res 1995, 55:498–500.
36. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del BM, De Santis M,
Manenti F: Natural history of inoperable hepatocellular carcinoma:
estrogen receptors’ status in the tumor is the strongest prognostic factor
for survival. Hepatology 2000, 32:233–238.
37. Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R, Ferretti I,
Manenti F: Estrogen receptor classification for hepatocellular carcinoma:
comparison with clinical staging systems. J Clin Oncol 2003, 21:441–446.
38. Han J, Ding L, Yuan B, Yang X, Wang X, Li J, Lu Q, Huang C, Ye Q: Hepatitis
B virus X protein and the estrogen receptor variant lacking exon 5
inhibit estrogen receptor signaling in hepatoma cells. Nucleic Acids Res
2006, 34:3095–3106.
39. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel
variant of ER-alpha, is expressed in ER-positive and -negative human
breast carcinomas. Anticancer Res 2008, 28:479–483.
40. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, Manno M,
Bertani H, Dugani A, Manenti F: Hormonal therapy with megestrol in
inoperable hepatocellular carcinoma characterized by variant oestrogen
receptors. Br J Cancer 2001, 84:881–885.
41. Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G:
Multidisciplinary approach for HCC patients: hepatology for the
oncologists. Ann Oncol 2013, 24(Suppl 2):i15–i23.
42. Farinati F, Cardin R, Bortolami M, Grottola A, Manno M, Colantoni A, Villa E:
Estrogens receptors and oxidative damage in the liver. Mol Cell
Endocrinol 2002, 193:85–88.
43. Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, Xu ZX, An LJ, Wang CP,
Zeng Z, Yang YP: Hypomethylation of long interspersed nuclear element-
1 promoter is associated with poor outcomes for curative resected
hepatocellular carcinoma. Liver Int 2013, 34:136–146.
44. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A: Hypomethylation of long
interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol
2009, 22:442–449.
45. Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, Okamura Y,
Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Fujii T,
Sugimoto H, Koike M, Fujiwara M, Takeda S, Kodera Y: Estrogen receptor 1
gene as a tumor suppressor gene in hepatocellular carcinoma detected
by triple-combination array analysis. Int J Oncol 2013, 43:88–94.
46. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP: DNA
methylation and environmental exposures in human hepatocellular
carcinoma. J Natl Cancer Inst 2002, 94:755–761.
47. Straub RH: The complex role of estrogens in inflammation. Endocr Rev
2007, 28:521–574.
48. Rogers A, Eastell R: The effect of 17beta-estradiol on production of
cytokines in cultures of peripheral blood. Bone 2001, 29:30–34.
49. Polan ML, Loukides J, Nelson P, Carding S, Diamond M, Walsh A, Bottomly
K: Progesterone and estradiol modulate interleukin-1 beta messenger
ribonucleic acid levels in cultured human peripheral monocytes.
J Clin Endocrinol Metab 1989, 69:1200–1206.
50. Kawasaki T, Ushiyama T, Inoue K, Hukuda S: Effects of estrogen on
interleukin-6 production in rheumatoid fibroblast-like synoviocytes.
Clin Exp Rheumatol 2000, 18:743–745.
51. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M:
Gender disparity in liver cancer due to sex differences in MyD88-
dependent IL-6 production. Science 2007, 317:121–124.
52. Rodriguez E, Lopez R, Paez A, Masso F, Montano LF: 17Beta-estradiol
inhibits the adhesion of leukocytes in TNF-alpha stimulated human
endothelial cells by blocking IL-8 and MCP-1 secretion, but not its
transcription. Life Sci 2002, 71:2181–2193.
Shi et al. Journal of Translational Medicine 2014, 12:93 Page 8 of 9
http://www.translational-medicine.com/content/12/1/9353. Kanda N, Watanabe S: 17beta-estradiol, progesterone, and
dihydrotestosterone suppress the growth of human melanoma by
inhibiting interleukin-8 production. J Invest Dermatol 2001, 117:274–283.
54. Gilmore W, Weiner LP, Correale J: Effect of estradiol on cytokine secretion
by proteolipid protein-specific T cell clones isolated from multiple sclerosis
patients and normal control subjects. J Immunol 1997, 158:446–451.
55. Liu HY, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, Vandenbark AA,
Offner H: Estrogen inhibition of EAE involves effects on dendritic cell
function. J Neurosci Res 2002, 70:238–248.
56. Kanda N, Tamaki K: Estrogen enhances immunoglobulin production by
human PBMCs. J Allergy Clin Immunol 1999, 103:282–288.
57. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL,
Spelsberg TC: Modulation of transforming growth factor-beta production
in normal human osteoblast-like cells by 17 beta-estradiol and
parathyroid hormone. Endocrinology 1991, 129:3313–3320.
58. Hatthachote P, Gillespie JI: Complex interactions between sex steroids
and cytokines in the human pregnant myometrium: evidence for an
autocrine signaling system at term. Endocrinology 1999, 140:2533–2540.
59. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, Prieto
J, Avila MA: The epidermal growth factor receptor: a link between
inflammation and liver cancer. Exp Biol Med (Maywood) 2009, 234:713–725.
60. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation.
Nature 2008, 454:436–444.
61. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A,
Zazzeroni F, Alesse E: The inflammatory microenvironment in
hepatocellular carcinoma: a pivotal role for tumor-associated macro-
phages. Biomed Res Int 2013, 2013:187204.
62. Prieto J: Inflammation, HCC and sex: IL-6 in the centre of the triangle.
J Hepatol 2008, 48:380–381.
63. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa
Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M: Serum IL-6 levels
and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an
analysis based on gender differences. Int J Cancer 2009, 125:2264–2269.
64. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK,
Sung JJ, Chan HL: High serum interleukin-6 level predicts future
hepatocellular carcinoma development in patients with chronic hepatitis
B. Int J Cancer 2009, 124:2766–2770.
65. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, Chi CW, Lui WY,
Lee SD: Evaluation of interleukin-6, interleukin-10 and human hepatocyte
growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg
Oncol 2007, 33:208–212.
66. Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B: miR-22
promotes HBV-related hepatocellular carcinoma development in males.
Clin Cancer Res 2011, 17:5593–5603.
67. Sun B, Karin M: NF-kappaB signaling, liver disease and hepatoprotective
agents. Oncogene 2008, 27:6228–6244.
68. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to
cancer development and progression. Nat Rev Immunol 2005, 5:749–759.
69. Stein B, Yang MX: Repression of the interleukin-6 promoter by estrogen
receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 1995,
15:4971–4979.
70. Lippitz BE: Cytokine patterns in patients with cancer: a systematic review.
Lancet Oncol 2013, 14:e218–e228.
71. Li Z, Tuteja G, Schug J, Kaestner KH: Foxa1 and Foxa2 are essential for
sexual dimorphism in liver cancer. Cell 2012, 148:72–83.
72. Sica A, Allavena P, Mantovani A: Cancer related inflammation: the
macrophage connection. Cancer Lett 2008, 267:204–215.
73. Calvisi DF: Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor
suppressive role of signal transducer and activator of transcription 3 in
liver cancer. Hepatology 2011, 54:9–12.
74. He G, Karin M: NF-kappaB and STAT3 - key players in liver inflammation
and cancer. Cell Res 2011, 21:159–168.
75. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM,
Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in
human HCC. Gastroenterology 2006, 130:1117–1128.
76. Fan Y, Mao R, Yang J: NF-kappaB and STAT3 signaling pathways
collaboratively link inflammation to cancer. Protein Cell 2013, 4:176–185.
77. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W,
Peck-Radosavljevic M, Leffert HL, Karin M: Hepatocyte IKKbeta/NF-kappaB
inhibits tumor promotion and progression by preventing oxidative
stress-driven STAT3 activation. Cancer Cell 2010, 17:286–297.78. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K,
Takaesu G, Maehara Y, Iida M, Yoshimura A: Deletion of the SOCS3 gene in
liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis.
Gastroenterology 2006, 131:179–193.
79. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G,
Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H: Inhibiting Stat3 signaling
in the hematopoietic system elicits multicomponent antitumor immunity.
Nat Med 2005, 11:1314–1321.
80. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X, Sun B:
Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma
progression by control of STAT3. Hepatology 2013, 57:678–688.
81. Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ, Holman
K, James SJ, Jacob ST, Plass C: Suppression of the protein tyrosine
phosphatase receptor type O gene (PTPRO) by methylation in
hepatocellular carcinomas. Oncogene 2003, 22:6319–6331.
82. Hsu SH, Motiwala T, Roy S, Claus R, Mustafa M, Plass C, Freitas MA, Ghoshal
K, Jacob ST: Methylation of the PTPRO gene in human hepatocellular
carcinoma and identification of VCP as its substrate. J Cell Biochem 2013,
114:1810–1818.
83. Sceusi EL, Loose DS, Wray CJ: Clinical implications of DNA methylation in
hepatocellular carcinoma. HPB (Oxford) 2011, 13:369–376.
84. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I,
Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of
aberrant methylation in the molecular pathogenesis of human
hepatocellular carcinoma. J Clin Invest 2007, 117:2713–2722.
85. Friedman JR, Kaestner KH: The Foxa family of transcription factors in
development and metabolism. Cell Mol Life Sci 2006, 63:2317–2328.
86. Sund NJ, Ang SL, Sackett SD, Shen W, Daigle N, Magnuson MA, Kaestner KH:
Hepatocyte nuclear factor 3beta (Foxa2) is dispensable for maintaining
the differentiated state of the adult hepatocyte. Mol Cell Biol 2000,
20:5175–5183.
87. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH:
Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and
results in endoplasmic reticulum stress. Nat Med 2008, 14:828–836.
88. Kaestner KH: The FoxA factors in organogenesis and differentiation.
Curr Opin Genet Dev 2010, 20:527–532.
89. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao
W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M:
Chromosome-wide mapping of estrogen receptor binding reveals long-
range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33–43.
90. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A,
Rennie PS, Matusik RJ: The role of hepatocyte nuclear factor-3 alpha
(forkhead box A1) and androgen receptor in transcriptional regulation of
prostatic genes. Mol Endocrinol 2003, 17:1484–1507.
91. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist MC, Matusik RJ:
Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate
and epididymal genes differentially. Ann N Y Acad Sci 2005, 1061:77–93.
92. Yager JD, Liehr JG: Molecular mechanisms of estrogen carcinogenesis.
Annu Rev Pharmacol Toxicol 1996, 36:203–232.
93. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W: microRNA-
22, downregulated in hepatocellular carcinoma and correlated with
prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer
2010, 103:1215–1220.
94. Pandey DP, Picard D: miR-22 inhibits estrogen signaling by directly
targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009,
29:3783–3790.
95. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ:
MicroRNA-18a prevents estrogen receptor-alpha expression, promoting
proliferation of hepatocellular carcinoma cells. Gastroenterology 2009,
136:683–693.
96. Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J, Cui D, Yu C, Cai Z: Tumor-
specific expression of microRNA-26a suppresses human hepatocellular
carcinoma growth via cyclin-dependent and -independent pathways.
Mol Ther 2011, 19:1521–1528.
97. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC: Estrogen
receptor beta inhibits human breast cancer cell proliferation and tumor
formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64:423–428.
98. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA:
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation
of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2004,
101:1566–1571.
Shi et al. Journal of Translational Medicine 2014, 12:93 Page 9 of 9
http://www.translational-medicine.com/content/12/1/9399. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC: Selective
estrogen receptor-beta agonists repress transcription of proinflammatory
genes. J Immunol 2008, 180:630–636.
100. Wang AG, Lee KY, Kim SY, Choi JY, Lee KH, Kim WH, Wang HJ, Kim JM, Park
MG, Yeom YI, Kim NS, Yu DY, Lee DS: The expression of estrogen
receptors in hepatocellular carcinoma in Korean patients. Yonsei Med J
2006, 47:811–816.
101. Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C, Wang D, Sun Y, Hu G, Lang Z,
Huang C, Yang X: HBsAg and HBx knocked into the p21 locus causes
hepatocellular carcinoma in mice. Hepatology 2004, 39:318–324.
102. Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantonelli
I, Rhonnstad P, Trozzi L, Apelqvist T, Gentile R, Candelaresi C, Fava G,
Semeraro R, Benedetti A, Gaudio E, Franchitto A, Onori P, De Minicis S,
Carpino G, Kallin E, Alvaro D, Nilsson S: An oestrogen receptor
beta-selective agonist exerts anti-neoplastic effects in experimental
intrahepatic cholangiocarcinoma. Dig Liver Dis 2012, 44:134–142.
103. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell
migration, invasion, and metastasis. Cell 2006, 124:263–266.
104. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages
in tumour progression: implications for new anticancer therapies.
J Pathol 2002, 196:254–265.
105. Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L, Shen P: Estrogen represses
hepatocellular carcinoma (HCC) growth via inhibiting alternative
activation of tumor-associated macrophages (TAMs). J Biol Chem 2012,
287:40140–40149.
106. Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, Tagliaferri M, Cohen I,
Speed TP, Leitman DC: Estrogen receptor beta binds to and regulates
three distinct classes of target genes. J Biol Chem 2010, 285:22059–22066.
107. Harada N, Ota H, Yoshimura N, Katsuyama T, Takagi Y: Localized aberrant
expression of cytochrome P450 aromatase in primary and metastatic
malignant tumors of human liver. J Clin Endocrinol Metab 1998,
83:697–702.
108. Castagnetta LA, Agostara B, Montalto G, Polito L, Campisi I, Saetta A, Itoh T,
Yu B, Chen S, Carruba G: Local estrogen formation by nontumoral,
cirrhotic, and malignant human liver tissues and cells. Cancer Res 2003,
63:5041–5045.
109. Granata OM, Cocciadifero L, Campisi I, Miceli V, Montalto G, Polito LM,
Agostara B, Carruba G: Androgen metabolism and biotransformation in
nontumoral and malignant human liver tissues and cells. J Steroid
Biochem Mol Biol 2009, 113:290–295.
110. Sasano H, Harada N: Intratumoral aromatase in human breast,
endometrial, and ovarian malignancies. Endocr Rev 1998, 19:593–607.
111. Gunson DE, Steele RE, Chau RY: Prevention of spontaneous tumours in
female rats by fadrozole hydrochloride, an aromatase inhibitor.
Br J Cancer 1995, 72:72–75.
112. Koh WP, Yuan JM, Wang R, Govindarajan S, Oppenheimer R, Zhang ZQ, Yu
MC, Ingles SA: Aromatase (CYP19) promoter gene polymorphism and risk
of nonviral hepatitis-related hepatocellular carcinoma. Cancer 2011,
117:3383–3392.
113. Paulson DF: Carcinoma of the prostate: the therapeutic dilemma.
Annu Rev Med 1984, 35:341–372.
114. Smolev JK, Coffey DS, Scott WW: Experimental models for the study of
prostatic adenocarcinoma. J Urol 1977, 118:216–220.
115. Hollingsworth AB, Lerner MR, Lightfoot SA, Wilkerson KB, Hanas JS, McCay
PB, Brackett DJ: Prevention of DMBA-induced rat mammary carcinomas
comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res
Treat 1998, 47:63–70.
116. Zumoff B: Does postmenopausal estrogen administration increase the
risk of breast cancer? Contributions of animal, biochemical, and clinical
investigative studies to a resolution of the controversy. Proc Soc Exp Biol
Med 1998, 217:30–37.
117. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocken C, Farrell G:
Constitutive activation of NF-kappaB in human hepatocellular carcinoma:
evidence of a cytoprotective role. Hum Gene Ther 2006, 17:280–290.
118. Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R, Shen P:
Oestrogen attenuates tumour progression in hepatocellular carcinoma.
J Pathol 2012, 228:216–229.119. Francavilla A, Polimeno L, Barone M, Azzarone A, Starzl TE: Hepatic
regeneration and growth factors. J Surg Oncol Suppl 1993, 3:1–7.
120. Kalaitzidis D, Gilmore TD: Transcription factor cross-talk: the estrogen
receptor and NF-kappaB. Trends Endocrinol Metab 2005, 16:46–52.
121. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK: The role
of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in
HepG2 cells. Endocrinology 2000, 141:3403–3411.
doi:10.1186/1479-5876-12-93
Cite this article as: Shi et al.: Role of estrogen in hepatocellular
carcinoma: is inflammation the key? Journal of Translational Medicine
2014 12:93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
